Integral Health Asset Management LLC Acquires Shares of 200,000 Silence Therapeutics plc (NASDAQ:SLN)

Integral Health Asset Management LLC acquired a new position in shares of Silence Therapeutics plc (NASDAQ:SLN - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 200,000 shares of the company's stock, valued at approximately $1,376,000. Integral Health Asset Management LLC owned 0.67% of Silence Therapeutics at the end of the most recent quarter.

Several other large investors have also modified their holdings of SLN. JPMorgan Chase & Co. bought a new stake in Silence Therapeutics in the 4th quarter valued at $26,000. GAMMA Investing LLC boosted its holdings in Silence Therapeutics by 609.2% in the 4th quarter. GAMMA Investing LLC now owns 6,092 shares of the company's stock valued at $42,000 after purchasing an additional 5,233 shares during the period. Barclays PLC boosted its holdings in Silence Therapeutics by 83.8% in the 4th quarter. Barclays PLC now owns 6,126 shares of the company's stock valued at $42,000 after purchasing an additional 2,793 shares during the period. China Universal Asset Management Co. Ltd. bought a new stake in Silence Therapeutics in the 4th quarter valued at $69,000. Finally, Virtus ETF Advisers LLC boosted its holdings in Silence Therapeutics by 130.5% in the 4th quarter. Virtus ETF Advisers LLC now owns 10,772 shares of the company's stock valued at $74,000 after purchasing an additional 6,098 shares during the period. 98.73% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

SLN has been the subject of a number of analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $75.00 price objective on shares of Silence Therapeutics in a report on Friday, March 7th. Chardan Capital reduced their price objective on shares of Silence Therapeutics from $55.00 to $35.00 and set a "buy" rating for the company in a report on Friday, May 9th. BMO Capital Markets reduced their price objective on shares of Silence Therapeutics from $67.00 to $25.00 and set an "outperform" rating for the company in a report on Tuesday, March 4th. Morgan Stanley reduced their price objective on shares of Silence Therapeutics from $45.00 to $25.00 and set an "overweight" rating for the company in a report on Friday, May 9th. Finally, The Goldman Sachs Group reduced their price objective on shares of Silence Therapeutics from $4.00 to $3.00 and set a "sell" rating for the company in a report on Friday, May 9th. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $33.83.

Silence Therapeutics Trading Down 1.2%

Shares of Silence Therapeutics stock traded down $0.05 during mid-day trading on Wednesday, reaching $4.06. 196,576 shares of the stock were exchanged, compared to its average volume of 299,307. The company has a market cap of $121.52 million, a price-to-earnings ratio of -2.59 and a beta of 1.20. The firm has a 50-day simple moving average of $3.34 and a 200 day simple moving average of $6.28. Silence Therapeutics plc has a fifty-two week low of $1.97 and a fifty-two week high of $24.38.

Silence Therapeutics (NASDAQ:SLN - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.42). The firm had revenue of $0.14 million for the quarter, compared to analyst estimates of $3.58 million. Silence Therapeutics had a negative return on equity of 62.81% and a negative net margin of 342.00%. On average, research analysts predict that Silence Therapeutics plc will post -1.77 EPS for the current fiscal year.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.